• THE YEAR IN REVIEW|
As an action-packed year within the HIV/AIDS field draws to a close, TheBodyPRO.com's sister site, TheBody.com, takes stock of 2010 in a new series of articles, "HIV/AIDS Year in Review: Looking Back on 2010 (and Ahead to 2011)." You can read the entire series here; below is a taste of what you'll find there.
Top HIV/AIDS Clinical Developments of 2010
Of the hundreds of published studies, presented research and other major developments in HIV this year, which are the most likely to change the way we approach HIV prevention or the care of our HIV-infected patients? In one of our most popular annual updates, David Wohl, M.D., takes an in-depth look at the highlights of 2010 and their clinical implications.
Strangest but Truest Posts of 2010 in TheBody.com's "Ask the Experts" Forums
As many of you reading this know all too well, we may be 30 years into the HIV pandemic, but a stunning number of people still don't know the first thing about HIV/AIDS. TheBody.com's "Ask the Experts" forums, where HIV-uninfected and infected individuals go for sound information from top HIV clinicians, is no stranger to odd, nonsensical questions about the virus and its transmission. Take a look at these 10 examples -- and vote for the ones you feel are most bizarre!
The Buzz Factor: Most Talked-About Stories on TheBody.com in 2010
Every year, TheBody.com publishes thousands of articles -- but a handful always stand out as the most popular, exciting or controversial among our readership. In this look back at 2010, we considered which articles got the most page views and comments, as well as which were shared the most or got the biggest responses on Facebook and Twitter.
Patient Perspective: My T Cells Could Use a Facelift
"Can I still complain about getting older if I was supposed to be dead 20 years ago?" Mark S. King asks. "That's the dilemma of aging, HIV-positive guys like me. Feeling victorious over AIDS only takes your self-esteem so far; there's no HIV medication to fight wrinkles."
Back to Top
• HIV TREATMENT & COMPLICATIONS
Once-Daily Raltegravir Fails to Stand Up Against Twice-Daily Dose
"It's hard to estimate how many patients with longstanding HIV infection have had their lives literally saved with raltegravir [Isentress]," writes Paul Sax, M.D., for Journal Watch. "But is it a once-daily drug? Probably not," based on newly released study results.
Planning an Immune-Friendly Diet? Don't Forget the Antioxidants
Although in HIV care we (by necessity) tend to focus on pharmaceutical interventions to ensure our patients' health, it goes without saying that a beneficial diet can also improve an individual's health and quality of life. Foods rich in antioxidants (or nutrients that can boost the body's own production of antioxidants) are believed to be particularly helpful -- but can they prove a boon for HIV-infected people in particular? A small U.S. study suggests that antioxidants may help boost CD4 count and decrease insulin resistance.
Understanding and Managing Peripheral Neuropathy
Peripheral neuropathy is the most common neurological disorder in HIV-infected people. It can be a major source of pain and discomfort -- and a reason for decreased antiretroviral adherence. In this overview from the San Francisco AIDS Foundation, Anne Monroe, M.D., M.S.P.H., explains how neuropathy develops and how it can be treated.
More Headlines on HIV Treatment & Complications:
Back to Top
• HIV NEWS & VIEWS
Why the ADAP Catastrophe Is About Far More than Waiting Lists
When people talk about the U.S.'s worsening AIDS Drug Assistance Program (ADAP) crisis, many tend to focus on the headline-grabbing issue: waiting lists. But those waiting lists are only part of the story -- and often a small part, at that. Test Positive Aware Network explains more about the ADAP emergency lying just beneath the surface.
More News Headlines:
Back to Top
• HIV/STD TRANSMISSION & TESTING
QD Dose of Tenofovir/Emtricitabine Reduces HIV Infection Risk by 44 Percent Among MSM, Study Finds
A daily dose of tenofovir/emtricitabine (Truvada) appears to reduce the risk of HIV infection among men who have sex with men (MSM) by about 44%, according to the results of a large international study. The study (called iPrEx) found that the protective effect of tenofovir/emtricitabine increased with stricter adherence.
Paul Sax, M.D.: A Clinician's Analysis of the iPrEx Study Results
The HIV prevention community is buzzing over the newly published results of the iPrEx study. Although the findings are thrilling, they also raise some important questions, including the cost of taking Truvada for prevention and how well the strategy would really work outside of a study. Paul Sax, M.D., offers a clinician's perspective on the story.
Global HIV/AIDS Pandemic Update Reveals Gains, But Many Obstacles
HIV incidence worldwide "has dropped by about one-fifth over the past decade, but millions of people are still missing out on major progress in prevention and treatment," according to UNAIDS' newly released annual report on the HIV/AIDS pandemic, Agence France-Presse reports. The report states that 2.6 million people worldwide became newly infected with HIV in 2009, an incidence rate about 19 percent lower than it was in 1999.
More Headlines on HIV/STD Transmission:
Back to Top